These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34414233)

  • 21. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
    Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
    J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.
    Witzel I; Graeser M; Karn T; Schmidt M; Wirtz R; Schütze D; Rausch A; Jänicke F; Milde-Langosch K; Müller V
    J Cancer Res Clin Oncol; 2013 May; 139(5):809-16. PubMed ID: 23392859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
    Dejeux E; Rønneberg JA; Solvang H; Bukholm I; Geisler S; Aas T; Gut IG; Børresen-Dale AL; Lønning PE; Kristensen VN; Tost J
    Mol Cancer; 2010 Mar; 9():68. PubMed ID: 20338046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.
    Arora A; Parvathaneni S; Aleskandarany MA; Agarwal D; Ali R; Abdel-Fatah T; Green AR; Ball GR; Rakha EA; Ellis IO; Sharma S; Madhusudan S
    Mol Cancer Ther; 2017 Jan; 16(1):239-250. PubMed ID: 27837030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
    Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
    Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.
    Zurita M; Lara PC; del Moral R; Torres B; Linares-Fernández JL; Arrabal SR; Martínez-Galán J; Oliver FJ; Ruiz de Almodóvar JM
    BMC Cancer; 2010 May; 10():217. PubMed ID: 20487521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer.
    Pavanelli AC; Mangone FR; Barros LRC; Machado-Rugolo J; Capelozzi VL; Nagai MA
    Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34209776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.
    Tabassum A; Samdani MN; Dhali TC; Alam R; Ahammad F; Samad A; Karpiński TM
    J Mol Med (Berl); 2021 Sep; 99(9):1293-1309. PubMed ID: 34047812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis.
    Dai JB; Zhu B; Lin WJ; Gao HY; Dai H; Zheng L; Shi WH; Chen WX
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32043523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
    Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
    BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
    Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
    Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
    Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of
    Chen C; Liu H; Xu Q; Zhang X; Mu F; Liu J
    Biomed Res Int; 2022; 2022():9386477. PubMed ID: 35789644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
    Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
    Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
    Liu R; Guo CX; Zhou HH
    Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.
    Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JM; Nicholson RI; Print CG; Clark SJ; Musgrove EA
    Mol Cancer Ther; 2013 Sep; 12(9):1874-85. PubMed ID: 23861345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
    Yardley DA; Peacock NW; Shastry M; Burris HA; Bechhold RG; Hendricks CB; Yoshizawa CN; Sing AP; Hainsworth JD
    Breast Cancer Res Treat; 2015 Nov; 154(2):299-308. PubMed ID: 26507191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.